Navigation Links
OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
Date:9/22/2010

on with docetaxel/prednisone, measuring the effect of custirsen on serum clusterin levels and describing time to progression and overall patient survival. Baseline characteristics were well balanced between the treatment arms.

About Custirsen

Custirsen is designed to inhibit the production of clusterin, a protein that is associated with cancer treatment resistance. In 2009, Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. entered into a global license and collaboration agreement to develop and commercialize custirsen. The global Phase 3 clinical programs include both the ongoing SATURN Phase 3 trial assessing durable pain palliation as the primary endpoint for second-line chemotherapy in men with metastatic CRPC and the upcoming SYNERGY Phase 3 trial assessing survival as the primary endpoint in men with metastatic CRPC receiving first-line chemotherapy. A third Phase 3 trial assessing survival as the primary endpoint in first-line treatment of advanced, unresectable non-small cell lung cancer (NSCLC) is also planned as part of the global clinical program to commercialize custirsen.

More information on the SATURN trial is available on the OncoGenex website at http://oncogenex.com/clinicalTrials/index.html.

Custirsen has received Fast Track designation from the U.S. Food and Drug Administration (FDA). Both the Prostate Cancer SATURN trial and the SYNERGY trial are being conducted through the Special Protocol Assessment (SPA) process. In addition, the European Medicines Agency indicated that the Committee for Medicinal Products for Human Use was in overall agreement with the custirsen development plan for commercialization.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Reports Second Quarter Financial Results
2. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
6. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
7. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
8. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
9. OncoGenex Reports Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 Follow ... level of each type of cholesterol carrier or lipoprotein ... presence of excessive cholesterol levels in the body, especially ... condition to heart attack and other cardiovascular disorders. Cardiovascular ... therefore testing for cholesterol levels on a regular basis, ...
(Date:9/30/2014)... Basel, Switzerland (PRWEB) September 30, 2014 ... advanced software solutions for drug discovery and ... the FUNGITECT consortium has chosen Genedata Selector ... next-generation sequencing (NGS) data. FUNGITECT is a ... of invasive fungal diseases via individualized anti-fungal ...
(Date:9/30/2014)... 2014 FemCap Inc., www.femcap.com  an innovator ... of a patent No: US, 8,795,248 B2 dated Aug. ... FDA clearance in the U.S., 510(K) K121857, medical device ... patent is related to its menstrual cup with a ... is releasing FemmyCycle Teen, a third menstrual cup to ...
(Date:9/30/2014)... 2014 Lyme Research Alliance ... disease research at universities, today announced the awarding of ... identification, treatment and cure for Lyme and other tick-borne ... most applications in its history—over 20 grant proposals—a 100 ... were pleased to receive so many solid applications from ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3The FemmyCycle 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4
... 29 Dawson James Securities, a,full- service investment ... coverage on CryoCor, Inc. (Nasdaq: CRYO ) ... price target of $6.00. John M.,Putnam, Sr. VP-Medical ... CryoCor,s recently FDA-approved cryoablation,system for atrial flutter and ...
... Pharmaxis,(ASX: PXS, Nasdaq: PXSL) today announced that its ... of people with bronchiectasis has met its two,primary ... Data from the 362 subject study demonstrated ... 12 weeks of treatment with Bronchitol,as assessed by ...
... Fund is Largest and First of its Kind in ... support initiatives,that enhance patient safety and quality of care, ... million to fund new and innovative programs,at hospitals, health ... is the largest and first of its kind given ...
Cached Biology Technology:Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 3Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care 2Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care 3
(Date:9/29/2014)... at home should use ventilation when cooking with a ... after a new study showed an association between gas ... bronchitis. , "In homes where a gas stove was ... is higher than in homes where a gas stove ... professor in the College of Public Health and Human ...
(Date:9/29/2014)... get a bad rap, and understandably so. The grain-of-rice-sized ... of millions of acres in the Western U.S. and ... to popular belief, these pests may not be to ... recently swept through the region. Instead, weather and topography ... fires than these bark-boring beetles. , New research led ...
(Date:9/29/2014)... Dr. Cristin Samper, president and CEO of the ... San Carlos. , The Order of San Carlos ... who have made outstanding contributions to the country, ... An international authority on conservation biology and environmental ... Residence in New York to receive the honor ...
Breaking Biology News(10 mins):Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 4
... Today, on behalf of the Association for Molecular Pathology ... US Food and Drug Administration,s (FDA) meeting on "Ultra ... to Assess Analytical Validity." As they begin developing their ... officials on many important considerations for evaluating analytical validity. ...
... Sea will promote fish stock recovery and increase fishermen,s incomes, ... York., In the North Sea up to 75 per cent ... result that many fisheries are now badly overfished. In comparison, ... and their fisheries are now some of the most prosperous ...
... LOS ALAMOS, New Mexico, June 22, 2011 Los Alamos ... 2011 R&D100 Awards. Recognized as the "Oscars of Invention" ... 100 proven technological advances of the past year. The ... specific nucleic acids, a spacer fluid for oil wells ...
Cached Biology News:AMP comments at FDA meeting on next-generation sequencing 2Discards ban 'will boost fisheries', says new research 2Los Alamos National Laboratory earns 3 R&D 100 Awards 2Los Alamos National Laboratory earns 3 R&D 100 Awards 3
... (Ribonuclease inhibitor) is a 50 ... inhibit RNase activity. It does ... activity. , Inhibits RNase ... template , Lacks DNA ...
...
... GC-rich nucleic acids ,The GC-RICH PCR ... and a proofreading polymerase, powers through templates ... with other polymerases and other blends of ... and the unique GC-RICH Resolution Solution combine ...
Chicken Aortic Smooth Muscle Cells (CAOSMC) (>500,000 cells)...
Biology Products: